BEAM (Beam Therapeutics) Insider Ownership: 1.74 % (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BEAM Beam Therapeutics Inc BEAM
71 GF Score
Price $27.56
GF Value $28.11
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Insider Ownership?

Beam Therapeutics BEAM +1.16% 71 Insider Ownership is 1.74 % as of Aug. 07, 2026. GuruFocus rates BEAM with a GF Score™ of 71/100 and a GF Value™ of $28.11 (Fairly Valued). The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Beam Therapeutics's insider ownership is 1.74%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Beam Therapeutics's Institutional Ownership is 104.70%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Beam Therapeutics's Float Percentage Of Total Shares Outstanding is 64.68%.

Beam Therapeutics Insider Ownership Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Insider Ownership Chart

Beam Therapeutics Historical Data

The historical data trend for Beam Therapeutics can be seen below:

2025-07-31 2025-08-31 2025-09-30 2025-10-31 2025-11-30 2026-01-31 2026-02-28 2026-05-31 2026-06-30 2026-07-31
Insider Ownership 1.61 1.61 1.61 1.61 1.61 1.59 1.57 1.72 1.76 1.74
BEAM
71GF Score
Beam Therapeutics Inc BEAM
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 1.74 % mean?
Beam Therapeutics (BEAM) has a Insider Ownership of 1.74 % as of Aug. 07, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Insider Ownership too high?
Beam Therapeutics' current Insider Ownership is 1.74 %. Overall, Beam Therapeutics has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Insider Ownership compare to KOD and TARS?
Beam Therapeutics' Insider Ownership of 1.74 % can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Biotechnology company?
A good Insider Ownership depends on the Biotechnology industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Insider Ownership is 1.74 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (BEAM) is currently considered Fairly Valued. The stock's GF Value™ is $28.11, compared to a current price of $27.56 — trading 2% below its estimated fair value. The current Insider Ownership is 1.74 %. Beam Therapeutics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Beam Therapeutics (BEAM), the current Insider Ownership is 1.74 % as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be undervalued. The current stock price of $27.56 is trading 2% below its estimated GF Value™ of $28.11. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for BEAM:

  • Insider Ownership: 1.74 %
  • GF Value™: $28.11 vs. price of $27.56 (2% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:Mexico
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
71GF Score

Get the complete analysis for BEAM

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.56
Price
$28.11
GF Value